Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

11/14/24 4:15:22 PM ET

$KNSA

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $KNSA alert in real time by email

SC 13G/A 1 tm2427721d2_sc13ga.htm SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

Kiniksa Pharmaceuticals International, plc

(f/k/a Kiniksa Pharmaceuticals, Ltd.)**

(Name of Issuer)

Class A Ordinary Shares, nominal value $0.000273235

(Title of Class of Securities)

G52694109**

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

x Rule 13d-1(c)

¨ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

**On June 27, 2024, Kiniksa Pharmaceuticals, Ltd. consummated redomiciliation transactions pursuant to which Kiniksa Pharmaceuticals International, plc became the successor issuer to Kiniksa Pharmaceuticals, Ltd. The CUSIP for the Class A ordinary shares of Kiniksa Pharmaceuticals International, plc is G52694109.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. G52694109


1.	Names of Reporting Persons I.R.S. Identification No. of Above Persons (Entities Only) Fairmount Funds Management LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 3,204,841⁽¹⁾
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 3,204,841⁽¹⁾
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,204,841⁽¹⁾
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 7.9%⁽²⁾
12.	Type of Reporting Person (See Instructions) IA

(1) The shares reported herein for the Reporting Person represent 3,204,841 shares of the Issuer’s Class A Ordinary Shares held by Fairmount Healthcare Fund II LP (“Fund II”).

(2) Calculated based on 40,608,972 shares of the Issuer’s Class A Ordinary Shares outstanding as of July 19, 2024, as disclosed on Form 10-Q filed by the Issuer with the Securities and Exchange Commission on July 25, 2024.

CUSIP No. G52694109


1.	Names of Reporting Persons I.R.S. Identification No. of Above Persons (Entities Only) Peter Harwin
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 3,204,841⁽¹⁾
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 3,204,841⁽¹⁾
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,204,841⁽¹⁾
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 7.9%⁽²⁾
12.	Type of Reporting Person (See Instructions) HC, IN

(1) The shares reported herein for the Reporting Person represent 3,204,841 shares of the Issuer’s Class A Ordinary Shares held by Fund II.

CUSIP No. G52694109


1.	Names of Reporting Persons I.R.S. Identification No. of Above Persons (Entities Only) Tomas Kiselak
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Slovak Republic
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 3,204,841⁽¹⁾
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 3,204,841⁽¹⁾
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,204,841⁽¹⁾
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 7.9%⁽²⁾
12.	Type of Reporting Person (See Instructions) HC, IN

(1) The shares reported herein for the Reporting Person represent 3,204,841 shares of the Issuer’s Class A Ordinary Shares held by Fund II.

CUSIP No. G52694109


1.	Names of Reporting Persons I.R.S. Identification No. of Above Persons (Entities Only) Fairmount Healthcare Fund II L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 3,204,841⁽¹⁾
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 3,204,841⁽¹⁾
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,204,841⁽¹⁾
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 7.9%⁽²⁾
12.	Type of Reporting Person (See Instructions) PN

(1) The shares reported herein for the Reporting Person represent 3,204,841 directly owned shares of the Issuer’s Class A Ordinary Shares.

Item 1.

(a)

Name of Issuer: Kiniksa Pharmaceuticals International, plc (f/k/a Kiniksa Pharmaceuticals, Ltd.)

(b)

Address of Issuer’s Principal Executive Offices: Clarendon House, 2 Church Street, Hamilton HM11, Bermuda.

Item 2.

This Amendment No. 2 to Schedule 13G amends and restates the statements on Schedule 13G originally filed on August 10, 2023 and Amendment No. 1 filed on February 14, 2024.

(a)

Name of Person(s) Filing: This joint statement on Schedule 13G is being filed by Fairmount Funds Management LLC (“Fairmount”), Peter Harwin, Tomas Kiselak, and Fairmount Healthcare Fund II L.P. (“Fund II”). Fairmount, Mr. Harwin, Mr. Kiselak, and Fund II are collectively referred to herein as the “Reporting Persons.”

The Class A Ordinary Shares reported herein includes Class A Ordinary Shares beneficially owned directly by Fund II. Fairmount Healthcare Fund II GP LLC is the general partner of Fund II. The controlling persons of Fairmount are Mr. Harwin and Mr. Kiselak. Fairmount serves as investment adviser for Fund II and may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the Issuer held by Fund II. Fund II has delegated to Fairmount the sole power to vote and the sole power to dispose of all securities held in Fund II’s portfolio, including the shares of the Issuer’s Class A Ordinary Shares reported herein. Because Fund II has divested voting and investment power over the reported securities and cannot revoke such delegation on less than 61 days’ notice, Fund II disclaims beneficial ownership of the securities for purposes of Section 13(d) of the Act and therefore disclaim any obligation to report ownership of the reported securities under Section 13(d) of the Act. As managing members of Fairmount, Mr. Harwin and Mr. Kiselak may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by Fairmount. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of the securities reported in this Schedule 13G Statement (the “Statement”) other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of the Statement shall not be deemed an admission that any of Fairmount, Mr. Harwin, or Mr. Kiselak is the beneficial owner of such securities for any other purpose.

(b)

Address of Principal Business Office: The principal business office of the Reporting Persons is c/o Fairmount Funds Management LLC, 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428.

(c)

Citizenship: Fairmount is a Delaware limited liability company. Mr. Harwin is a United States citizen. Mr. Kiselak is a Slovak Republic citizen. Fund II is a Delaware limited partnership.

(d)

Title of Class of Securities: Class A Ordinary Shares, par value $0.000273235 (“Class A Ordinary Shares”)

	(e)	CUSIP Number: G52694109

Item 3.		If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

(a)	¨	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	¨	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	¨	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	¨	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	¨	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f)	¨	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g)	¨	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h)	¨	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)	¨	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	¨	A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
(k)	¨	Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: _______________.

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)	Amount Beneficially Owned:
	See the response(s) to Item 9 on the attached cover page(s).

(b)	Percent of Class:
	See the response(s) to Item 11 on the attached cover page(s).

(c)	Number of shares as to which such person has:

	(i)	sole power to vote or to direct the vote:
		See the response(s) to Item 5 on the attached cover page(s).

	(ii)	shared power to vote or to direct the vote
		See the response(s) to Item 6 on the attached cover page(s).

	(iii)	sole power to dispose or to direct the disposition of
		See the response(s) to Item 7 on the attached cover page(s).

	(iv)	shared power to dispose or to direct the disposition of
		See the response(s) to Item 8 on the attached cover page(s).

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable.

Item 8.

Identification and Classification of Members of the Group

Not applicable.

Item 9.

Notice of Dissolution of Group

Not applicable.

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 14, 2024

FAIRMOUNT FUNDS MANAGEMENT LLC

By:	/s/ Peter Harwin	/s/Tomas Kiselak
Name:	Peter Harwin	Tomas Kiselak
Title:	Managing Member	Managing Member

PETER HARWIN

By:	/s/ Peter Harwin

TOMAS KISELAK

By:	/s/Tomas Kiselak

FAIRMOUNT HEALTHCARE FUND II L.P. By: Fairmount Healthcare Fund II GP LLC

By:	/s/ Peter Harwin	/s/Tomas Kiselak
Name:	Peter Harwin	Tomas Kiselak
Title:	Member	Member

Exhibit A

Joint Filing Agreement

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned and each other person executing this joint filing agreement (this “Agreement”) agree as follows:

(i) The undersigned and each other person executing this Agreement are individually eligible to use the Schedule 13G to which this Exhibit is attached and such Schedule 13G is filed on behalf of the undersigned and each other person executing this Agreement; and

(ii) The undersigned and each other person executing this Agreement are responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of the undersigned or any other person executing this Agreement is responsible for the completeness or accuracy of the information statement concerning any other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all of which, taken together, shall constitute one and the same instrument.

Dated: November 14, 2024

FAIRMOUNT FUNDS MANAGEMENT LLC

By:	/s/ Peter Harwin	/s/Tomas Kiselak
Name:	Peter Harwin	Tomas Kiselak
Title:	Managing Member	Managing Member

PETER HARWIN

By:	/s/ Peter Harwin

TOMAS KISELAK

By:	/s/Tomas Kiselak

FAIRMOUNT HEALTHCARE FUND II L.P. By: Fairmount Healthcare Fund II GP LLC

By:	/s/ Peter Harwin	/s/Tomas Kiselak
Name:	Peter Harwin	Tomas Kiselak
Title:	Member	Member

Get the next $KNSA alert in real time by email

Date

Price Target

Rating

Analyst

3/13/2025

$40.00

Buy

Citigroup

9/13/2024

$40.00

Buy

Jefferies

5/3/2024

$34.00

Overweight

Wells Fargo

12/29/2021

$37.00 → $34.00

Buy

B of A Securities

Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

11/14/24 4:15:22 PM ET

$KNSA

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $KNSA alert in real time by email

SC 13G/A 1 tm2427721d2_sc13ga.htm SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

Kiniksa Pharmaceuticals International, plc

(f/k/a Kiniksa Pharmaceuticals, Ltd.)**

(Name of Issuer)

Class A Ordinary Shares, nominal value $0.000273235

(Title of Class of Securities)

G52694109**

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

x Rule 13d-1(c)

¨ Rule 13d-1(d)

CUSIP No. G52694109


1.	Names of Reporting Persons I.R.S. Identification No. of Above Persons (Entities Only) Fairmount Funds Management LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 3,204,841⁽¹⁾
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 3,204,841⁽¹⁾
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,204,841⁽¹⁾
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 7.9%⁽²⁾
12.	Type of Reporting Person (See Instructions) IA

(1) The shares reported herein for the Reporting Person represent 3,204,841 shares of the Issuer’s Class A Ordinary Shares held by Fairmount Healthcare Fund II LP (“Fund II”).

CUSIP No. G52694109


1.	Names of Reporting Persons I.R.S. Identification No. of Above Persons (Entities Only) Peter Harwin
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 3,204,841⁽¹⁾
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 3,204,841⁽¹⁾
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,204,841⁽¹⁾
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 7.9%⁽²⁾
12.	Type of Reporting Person (See Instructions) HC, IN

(1) The shares reported herein for the Reporting Person represent 3,204,841 shares of the Issuer’s Class A Ordinary Shares held by Fund II.

CUSIP No. G52694109


1.	Names of Reporting Persons I.R.S. Identification No. of Above Persons (Entities Only) Tomas Kiselak
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Slovak Republic
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 3,204,841⁽¹⁾
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 3,204,841⁽¹⁾
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,204,841⁽¹⁾
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 7.9%⁽²⁾
12.	Type of Reporting Person (See Instructions) HC, IN

(1) The shares reported herein for the Reporting Person represent 3,204,841 shares of the Issuer’s Class A Ordinary Shares held by Fund II.

CUSIP No. G52694109


1.	Names of Reporting Persons I.R.S. Identification No. of Above Persons (Entities Only) Fairmount Healthcare Fund II L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 3,204,841⁽¹⁾
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 3,204,841⁽¹⁾
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,204,841⁽¹⁾
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 7.9%⁽²⁾
12.	Type of Reporting Person (See Instructions) PN

(1) The shares reported herein for the Reporting Person represent 3,204,841 directly owned shares of the Issuer’s Class A Ordinary Shares.

Item 1.

(a)

Name of Issuer: Kiniksa Pharmaceuticals International, plc (f/k/a Kiniksa Pharmaceuticals, Ltd.)

(b)

Address of Issuer’s Principal Executive Offices: Clarendon House, 2 Church Street, Hamilton HM11, Bermuda.

Item 2.

This Amendment No. 2 to Schedule 13G amends and restates the statements on Schedule 13G originally filed on August 10, 2023 and Amendment No. 1 filed on February 14, 2024.

(a)

(b)

Address of Principal Business Office: The principal business office of the Reporting Persons is c/o Fairmount Funds Management LLC, 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA 19428.

(c)

Citizenship: Fairmount is a Delaware limited liability company. Mr. Harwin is a United States citizen. Mr. Kiselak is a Slovak Republic citizen. Fund II is a Delaware limited partnership.

(d)

Title of Class of Securities: Class A Ordinary Shares, par value $0.000273235 (“Class A Ordinary Shares”)

	(e)	CUSIP Number: G52694109

Item 3.		If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

(a)	¨	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	¨	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	¨	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	¨	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	¨	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f)	¨	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g)	¨	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h)	¨	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)	¨	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	¨	A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
(k)	¨	Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: _______________.

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)	Amount Beneficially Owned:
	See the response(s) to Item 9 on the attached cover page(s).

(b)	Percent of Class:
	See the response(s) to Item 11 on the attached cover page(s).

(c)	Number of shares as to which such person has:

	(i)	sole power to vote or to direct the vote:
		See the response(s) to Item 5 on the attached cover page(s).

	(ii)	shared power to vote or to direct the vote
		See the response(s) to Item 6 on the attached cover page(s).

	(iii)	sole power to dispose or to direct the disposition of
		See the response(s) to Item 7 on the attached cover page(s).

	(iv)	shared power to dispose or to direct the disposition of
		See the response(s) to Item 8 on the attached cover page(s).

Item 5.

Ownership of Five Percent or Less of a Class

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable.

Item 8.

Identification and Classification of Members of the Group

Not applicable.

Item 9.

Notice of Dissolution of Group

Not applicable.

Item 10.

Certification

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 14, 2024

FAIRMOUNT FUNDS MANAGEMENT LLC

By:	/s/ Peter Harwin	/s/Tomas Kiselak
Name:	Peter Harwin	Tomas Kiselak
Title:	Managing Member	Managing Member

PETER HARWIN

By:	/s/ Peter Harwin

TOMAS KISELAK

By:	/s/Tomas Kiselak

FAIRMOUNT HEALTHCARE FUND II L.P. By: Fairmount Healthcare Fund II GP LLC

By:	/s/ Peter Harwin	/s/Tomas Kiselak
Name:	Peter Harwin	Tomas Kiselak
Title:	Member	Member

Exhibit A

Joint Filing Agreement

This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, but all of which, taken together, shall constitute one and the same instrument.

Dated: November 14, 2024

FAIRMOUNT FUNDS MANAGEMENT LLC

By:	/s/ Peter Harwin	/s/Tomas Kiselak
Name:	Peter Harwin	Tomas Kiselak
Title:	Managing Member	Managing Member

PETER HARWIN

By:	/s/ Peter Harwin

TOMAS KISELAK

By:	/s/Tomas Kiselak

FAIRMOUNT HEALTHCARE FUND II L.P. By: Fairmount Healthcare Fund II GP LLC

By:	/s/ Peter Harwin	/s/Tomas Kiselak
Name:	Peter Harwin	Tomas Kiselak
Title:	Member	Member

Get the next $KNSA alert in real time by email

Date

Price Target

Rating

Analyst

3/13/2025

$40.00

Buy

Citigroup

9/13/2024

$40.00

Buy

Jefferies

5/3/2024

$34.00

Overweight

Wells Fargo

12/29/2021

$37.00 → $34.00

Buy

B of A Securities

Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for
$KNSA

Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

Crush Q3 2025 with the Best AI Executive Assistant

Recent Analyst Ratings for
$KNSA

$KNSA
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Kiniksa Pharmaceuticals International plc

SEC Form 144 filed by Kiniksa Pharmaceuticals International plc

Kiniksa Pharmaceuticals International plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

$KNSA
Press Releases

Fastest customizable press release news feed in the world

Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

$KNSA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Citigroup initiated coverage on Kiniksa Pharmaceuticals with a new price target

Jefferies initiated coverage on Kiniksa Pharmaceuticals with a new price target

Wells Fargo initiated coverage on Kiniksa Pharmaceuticals with a new price target

$KNSA
Financials

Live finance-specific insights

Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution

$KNSA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Levy Richard S converted options into 1,101 units of Class A Ordinary Share, increasing direct ownership by 6% to 18,474 units (SEC Form 4)

CHIEF OPERATING OFFICER Tessari Eben exercised 6,500 units of Class A Ordinary Share at a strike of $8.83 and sold $489,244 worth of Class A Ordinary Share (17,300 units at $28.28), decreasing direct ownership by 15% to 61,563 units (SEC Form 4)

Director Quart Barry D exercised 27,448 units of Class A Ordinary Share at a strike of $3.80 and sold $833,001 worth of Class A Ordinary Share (27,448 units at $30.35) (SEC Form 4)

$KNSA
Large Ownership Changes

This live feed shows all institutional transactions in real time.